Investor Relations
Corporate Profile
We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Copyright West LLC. Minimum 15 minutes delayed.
July 2, 2019
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...
June 24, 2019
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-st...
June 19, 2019
Akero Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO , June 19, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-s...
May 29, 2019
Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH
SAN FRANCISCO, May 29, 2019 /PRNewswire/ -- Akero Therapeutics, Inc., a biotechnology company develo...
May 1, 2019
Akero Therapeutics Appoints Bill White as CFO and Head of Corporate Development
White is a Life Sciences Investment Banking Veteran San Francisco, CA – Akero Therapeutics, Inc., a ...
April 23, 2019
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
Henderson is CFO of Turnstone Biologics San Francisco, CA – Akero Therapeutics, Inc., a biotechnolog...